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1. Introduction
Allergic rhinitis (AR) is a major chronic respiratory 
disease (1). Its prevalence, impact on quality of life, and 
association with comorbidities, such as asthma, are 
important (1). AR is caused by inflammation in the nasal 
mucosa, and appears as a type-1 hypersensitivity reaction. 
Approximately 50%–80% of all cases of rhinitis are due to 
AR (2). AR appears to be more prevalent in urban than in 
rural areas (2,3). Worldwide prevalence of AR is 25%–35% 
(4), whereas it is 15% in Turkey, and tends to be higher in 
children and young adults (5).
AR is characterized by sneezing, rhinorrhea, nasal 
itching, and nasal congestion (6). These symptoms 
occur because of mediator (histamine, prostaglandins, 
leukotrienes, cytokines, chemotactic factors) release 
from inflammatory cells that migrate to the nasal mucosa 
(6). The effects of topical corticosteroids are inhibition 
of aggregation of inflammatory cells in the airway, 
suppression of local production of cytokines, prevention 
of mediator release, and repair of the structure of the nasal 
mucosa (7).
Corticosteroids administered within the nasal cavity 
((intranasal corticosteroids (ICs)) have been used as an 
effective and safe treatment for various diseases of nasal 
sinuses (e.g., AR, vasomotor rhinitis) since the 1970s (8). 
AR incidence is increasing in tandem with the use of ICs. 
Many patients use ICs for months or years (9). Side effects 
are often reported for ICs, and include burning sensations, 
dryness, bleeding, and septal perforation within the nose 
(8,10–12). Atrophic changes in the nasal mucosa have been 
noted, especially in the first 4 weeks of IC treatment (13). 
However, the mechanism of action of this side effect is not 
known. 
Deoxyribonucleic acid (DNA) is very sensitive to 
damage and is the target of various reactive molecules. 
DNA damage, also known as genotoxic damage, can be 
spontaneous during DNA metabolism or can be attributed 
to the effects of environmental factors. It has been implicated 
in numerous diseases, such as cancer and inflammatory 
diseases, and is evaluated when monitoring chronic 
degenerative diseases, effectiveness of chemotherapy and 
radiotherapy, and genotoxic effects of medications. 
Background/aim: Allergic rhinitis (AR) is a respiratory disease caused by inflammation of the nasal mucosa. Intranasal corticosteroids 
(ICs) are an effective treatment for AR; however, their use has been associated with atrophy in nasal mucosae. Because DNA damage 
has been linked to several chronic diseases, we hypothesize that use of ICs could cause DNA damage in nasal mucosa cells, leading to 
mucosal atrophy and septal perforation.
Materials and methods: Sixty patients with moderate or severe AR were divided randomly into two groups. Mometasone furoate (MF) 
and antihistamine tablets (desloratadine) were given to the study (IC) group. Physiologic saline and desloratadine were given to the 
control ((serum physiologic (SP)) group. Nasal irrigation fluid was taken from patients before study commencement and after 4 weeks 
of treatment. The comet assay was applied to detect DNA damage in nasal mucosa cells.
Results: Nineteen patients were excluded, leaving a study population of 41 patients (IC group: 17 patients; SP group: 24 patients). 
Genotoxic damage was evaluated by comet assay. 
Conclusion: Treatment with MF spray for 4 weeks does not cause DNA breaks within cells in the nasal mucosa. These results could form 
the basis of clinical trials involving treatment with different ICs over longer treatment periods.
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The comet assay, also known as alkaline single cell gel 
electrophoresis (SCGE), is a noninvasive, rapid, precise 
fluorescent microscopic method. It can be applied to 
detect DNA damage and different cell types as well as 
determining the extent and type of damage. 
Our hypothesis is that side effects in the nose, such as 
mucosal atrophy and septal perforation, are dependent on 
DNA damage, which can lead to apoptosis. The purpose 
of our study was to investigate the use of mometasone 
furoate (6) (MF; an active ingredient of an IC, commonly 
used in Turkey), its efficacy, and the pathophysiology of its 
side effects.
2. Materials and methods
The present study was conducted in collaboration with 
the Departments of Otolaryngology, Pediatric Allergy, 
and Medical Biology of the Faculty of Medicine, Başkent 
University, Ankara, Turkey. This study was approved by 
the Institutional Review Board and Ethics Committee 
of Başkent University (Project No. KA14/203). It was 
a prospective, controlled, double-blind clinical study. 
All participants were informed about the methods and 
potential risks of the study. Written informed consent was 
provided by all subjects.
2.1. Patients
The study was carried out between September 2014 and 
April 2015. The inclusion criteria were as follows: diagnosis 
of moderate or severe AR, according to allergic rhinitis 
and its impact on asthma (ARIA) criteria (14); positive 
(>3 mm) skin-prick test or epicentral leather-prick test, 
undertaken by the Pediatric Allergy Department and 
indicating medical treatment; males or females aged 18–
65 years; history of AR symptoms (sneezing, rhinorrhea, 
nasal itching, nasal congestion); no use of systemic or 
topical corticosteroids in the previous month; and no viral 
or bacterial infections of the upper airways in the previous 
month.
We excluded patients who consumed alcohol or smoked 
tobacco; were undergoing immunotherapy or systemic 
immunosuppressive therapy; were using antihistamines, 
leukotriene antagonists, anti-lgE monoclonal antibodies, 
or decongestant drugs; were suffering from diabetes 
mellitus, asthma, cancer, cystic fibrosis, or other chronic 
inflammatory diseases; had advanced deviation of the nasal 
septum, nasal polyps, nasopharyngeal disease, or who had 
undergone nasal surgery previously; had infection of the 
upper respiratory tract during the first month of treatment; 
were suffering from epistaxis; or were pregnant.
Sixty patients met the inclusion criteria. The patients 
had not used any treatment for allergic rhinitis before. 
They were randomly divided into two groups using 
the sealed envelope method. IC and antihistamine 
tablets (desloratadine) were given to the study (IC) 
group. Physiologic (0.9%) saline and antihistamine 
tablets (desloratadine) were given to the control (serum 
physiologic (SP)) group. Identical antihistamine tablets 
were given to both groups, so that patients diagnosed with 
AR were not left untreated and the homogeneity of the two 
groups was ensured. Mechanical trauma was supplied by 
administration of IC spray to the IC group and physiologic 
serum spray to the SP group. Patients used the IC spray 
or physiologic serum spray every day for 4 weeks at an 
identical frequency and in equal doses. Each group used a 
single dose of the same antihistamine on 1 day during the 
4 weeks. In the IC group, patients administered two puffs 
of IC spray (MF) into each nasal passage in the morning 
and evening. Each spray provided 100 µg of MF to the 
nasal passage. In the SP group, patients administered two 
puffs of 0.9% sodium chloride into each nasal passage in 
the morning and evening.
Cells from the nasal mucosae of patients were obtained 
before study commencement and at the end of 4 weeks of 
treatment. Patients were asked not to wipe their noses on 
the morning that samples were to be taken. Patients were 
seated, 3.5 mL of saline was injected (using a 5-mL injector) 
into the right nasal passage, and a sterile container was used 
to collect the nasal wash. Then the curettage procedure was 
performed 2–3 times to the right nasal passage to release 
cells, and 3.5 mL of saline was injected into the right nasal 
passage by providing flow-exposed cells in the container. 
The same process was applied to the left nasal passage, and 
all nasal wash fluid was collected in the same container. 
The resultant nasal wash fluid was taken to the Medical 
Biology Laboratory on the same day. Absence or presence 
of genotoxic damage to cells (15,16), obtained from nasal 
wash fluid from both groups, was determined using CA 
(17–21) by a researcher who was not involved in sample 
procurement.
2.2. Alkaline comet assay (alkaline single cell gel 
electrophoresis) 
For the determination of genotoxic damages of patients, 
alkaline SCGE was performed as previously described 
(22). In brief, nasal wash fluids were centrifuged at 500 × 
g for 10 min. Supernatants were removed and cell pellets 
were resuspended in phosphate-buffered saline (PBS). Cell 
suspension, mixed with low melting point agarose (LMPA; 
Sigma–Aldrich, USA), was added onto the slides, which 
had been precoated with normal melting point agarose 
(NMPA; Sigma–Aldrich, USA). Coverslips were placed 
and were removed after the solidification of the agarose. 
Finally, a third layer of NMPA was added over the slides. 
After solidification of the third layer of NMPA, slides were 
incubated in a lysis solution at 4 °C (dark) for 2 h. Slides 
were incubated in an alkaline electrophoresis buffer for 
20 min in the dark, and electrophoresis was performed at 
24 V (300 mA) for 30 min. Slides were neutralized in a 
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neutralization buffer and stained with 2 µg/mL ethidium 
bromide. Cells were scored under fluorescence microscope 
(Nikon, Eclipse 600, Japan). A minimum of two SCGE 
slides were prepared from each sample and 300 nuclei were 
evaluated by visual scoring. Nuclei were scored as 0, 1+, 2+, 
3+, and 4+ by a blinded observer, according to the apparent 
relative proportion of DNA in the tail and head, as shown 
in Figures 1–5. Each counted nucleus was multiplied by its 
score, and total scores were expressed as AU.
2.3. Statistical analyses
Data analyses were undertaken using SPSS 11.5 (SPSS 
Inc., Chicago, IL, USA). Continuous and discontinuous 
numerical variables were investigated for normal and 
nonnormal distribution, using the Kolmogorov–Smirnov 
test. Significance of differences among groups for mean and 
median values was ascertained with the Mann–Whitney 
U-test. Categorical variables were analyzed with Pearson’s 
chi-square test or Fisher’s exact test. Correlation between 
continuous and discontinuous variables was ascertained 
using Spearman’s correlation test. A value of P < 0.05 was 
considered significant. 
3. Results
Among the 60 patients at study commencement, 9 patients 
did not attend for treatment, epistaxis was observed in 
one patient, and respiratory tract infection was observed 
in 9 patients. Hence, 19 patients were excluded from the 
study, leaving a study population of 41 patients. Seventeen 
patients (41.46%) were in the IC group ((8 female (19.51%) 
and 9 male (21.95%)). Twenty-four patients (58.54) were in 
the SP group ((14 female (34.15%) and 10 male (24.39%)). 
The sex distribution of patients is shown in Table 1. There 
was no significant difference between groups in terms of 
sex (P > 0.05). The age range of 41 patients was 20–58 years 
(median, 27; mean, 30.70 ± 9.31). The age range of the IC 
group was 20–51 years (median, 27; mean, 30.18 ± 9.07), 
whereas that of the SP group was 20–58 years (28; 31.08 ± 
9.65). The age distribution of the patients is shown in Table 
2. There was no significant difference between the groups 
in terms of age (P > 0.05). 
Mean comet score for 41 patients was 44.03 ± 21.72 
before treatment and 49.38 ± 19.25 after treatment. Mean 
comet score was 43.96 ± 25.34 before treatment and 48.07 
± 23.99 after treatment in the IC group. Mean comet score 
was 44.08 ± 19.33 before treatment and 50.30 ± 15.55 after 
treatment in the SP group. No significant difference was 
observed before and after treatment for mean comet scores 
within or between groups (P = 0.272). The comet scores of 
the patients are shown in Table 3.
4. Discussion
ICs have been used for the treatment of AR since the 
1970s. The clinical effects of topical corticosteroids are 
Figure 1. Appearance of a cell with comet scoring 0.
Figure 2. Appearance of a cell with comet scoring 1+.
Figure 3. Appearance of a cell with comet scoring 2+.
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associated with inhibition of aggregation of inflammatory 
cells in the airway, suppression of local production of 
cytokines, prevention of mediator release, and repair of 
nasal mucosal structure. Intranasal glucocorticosteroids 
are well-tolerated drugs and carry a low prevalence of 
side effects compared with placebo (23–25). The synthetic 
corticosteroids MF, beclomethasone dipropionate, 
betamethasone, dexamethasone, and hydrocortisone have 
been shown to be potent against AR (26). MF is a topical 
corticosteroid used commonly in AR treatment (27). In 
our study, MF was used for 1 month by AR patients. 
Intranasal glucocorticosteroids ameliorate AR 
symptoms, but use of certain ICs can lead to local 
histopathologic changes (28,29).
Side effects in the nasal cavity are often seen with 
intranasal glucocorticosteroids. These include epithelial 
irritation, burning sensations, dryness, crusting, 
epistaxis, and septal perforation (8,10–12,30,31). In our 
study, no patients suffered from headaches, nasal dryness, 
or nasal irritation, but epistaxis was seen in one patient, 
which merited exclusion from the study. It is thought 
that epistaxis after IC use is due to dryness and thinning 
of nasal mucosae (32,33). However, in a clinical study 
by Waddell et al. (34), ICs and placebo were compared 
and the prevalence of epistaxis was similar. Therefore, 
epistaxis after IC use is thought to be due to exposure 
of the nasal septum or anterior nasal concha to nasal 
applicators. 
Figure 4. Appearance of a cell with comet scoring 3+. Figure 5. Appearance of a cell with comet scoring 4+.
Table 1. Sex distribution of patients.
Male Female Total
Number % Number % Number %
SP 10 24.39 14 34.15 24 58.54
MF 9 21.95 8 19.51 17 41.46
Total 19 46.34 22 53.66 41 100
Table 2. Age distribution of patients.
Mean Number Std. [±] Median Minimum Maximum
SP 31.08 24 9.65 28.00 20.00 58.00
MF 30.18 17 9.07 27.00 20.00 51.00
Total 30.70 41 9.31 27.00 20.00 58.00
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Another problem considered to be associated with 
IC use is mucosal atrophy. Davies et al. (35) showed no 
atrophy in the nasal mucosa due to long-term use of MF 
nasal spray, and no reduction in epithelial thickness was 
observed in biopsies of nasal mucosae. In another study, 
atrophy in nasal mucosae was not detected after treatment 
with MF nasal spray for 12 months in AR patients (31). 
Minshall et al. (36) administered MF for 12 months to 69 
patients with perennial rhinitis, and did not detect changes 
in epithelial thickness, distribution and density of goblet 
cells, morphologic characteristics of glands and vessels in 
the lamina propria, or integrity of basal membranes. They 
found that use of nasal spray improved the appearance of 
the epithelium and reduced the prevalence of inflammatory 
cell infiltrates (especially those containing eosinophils and 
mast cells). 
Several scholars have investigated whether ICs cause 
histopathologic changes. Pipkorn et al. (37) showed 
that short-term application of sprays containing MF or 
budesonide to rat nasal mucosae did not cause significant 
histopathologic changes. Güngör et al. (38) did not 
observe significant differences in edema, ciliary loss, 
or intraepithelial loss by use of budesonide in rat nasal 
mucosae. Benninger et al. (39) reported that ICs did not 
cause mucosal atrophy or nasal septal perforation. Cervin 
et al. (8) reported that IC sprays used for AR treatment 
cause atrophy of nasal mucosae and increase the risk of 
septal perforation. 
In our study, we wished to ascertain whether MF nasal 
spray causes mucosal atrophy or not by observing DNA 
damage in nasal mucosa cells. We did not find a significant 
difference between the SP and IC groups in terms of DNA 
damage, which suggests that MF does not cause mucosal 
atrophy.  
IC (e.g., MF, fluticasone propionate, fluticasone 
furoate) use elicits minimal systemic exposure (<1%) 
due to their pharmacokinetic properties, and so systemic 
side effects are very limited (40). MF is an effective local 
antiinflammatory topical glucocorticosteroid and is not 
active systemically. Systemic effects have not been shown 
in children, adolescents, or adults. MF suspensions 
show little absorption in the gastrointestinal system, and 
absorbed MF is excreted from urinary and biliary systems 
by first-pass metabolism (31) Smith et al. (41) showed that 
MF has high affinity for glucocorticoid receptors and that 
its systemic absorption is minimal; thus it has minimal 
side effects. In our study, MF nasal spray was used for 
AR treatment because it would not lead to systemic side 
effects. 
Studies have shown that MF does not lead to DNA 
damage in rat liver cells and that it is not genotoxic (31). 
We found that MF did not cause DNA damage to nasal 
Table 3. Comet scores of patients.
Mean Std     Number P
Before
SP
Male 47.25 19.41 10
0.272
Female 41.81 19.68 14
Total 44.08 19.33 24
MF
Male 40.21 21.38 8
Female 47.29 29.29 9
Total 43.96 25.34 17
Total
Male 44.12 20.01 18
Female 43.96 23.42 23
Total 44.03 21.72 41
After
SP
Male 50.88 11.42 10
Female 49.89 18.36 14
Total 50.31 15.55 24
MF
Male 54.58 24.30 8
Female 42.29 23.55 9
Total 48.07 23.99 17
Total
Male 52.53 17.77 18
Female 46.92 20.38 23
Total 49.38 19.25 41
344
AKKAŞ et al. / Turk J Med Sci
mucosa cells in either group after 4 weeks of treatment. 
Hence, MF nasal spray seems to be safe for AR treatment. 
In our study, SCGE was used for the determination of 
DNA breaks because it is rapid, inexpensive, and only a 
small number of cells was available for analyses. SCGE is 
a simple, rapid, and sensitive method that can be applied 
to different types of cells and DNA damage. It does not 
require radioactive labeling, so it is often the preferred 
method of measurement of DNA damage (18). Another 
advantage is that SCGE allows the determination of DNA 
breaks with small amounts of cells from human biopsies. 
Moreover, the cost of equipment is lower than that of other 
test methods of genotoxicity (21). In comparison to other 
methods of genotoxicity testing, it can detect DNA damage 
at lower levels and with higher sensitivity. Use of SCGE 
in genotoxicity studies has increased gradually thanks to 
such advantages (42).
Nevertheless, SCGE has disadvantages. Certain 
differences (agarose concentration, number of applied 
cells, electrophoresis time) at technical implementation 
can affect results, and there can be differences among 
results from different laboratories even if the same 
protocol is applied (43). These differences occur primarily 
because of the subjective nature of comet classification. 
Therefore, comet counting must be undertaken by the 
same experienced researcher throughout the study (18), as 
was achieved in the present study. 
In conclusion, we have shown, for the first time, that 
treatment with MF spray for 4 weeks does not cause DNA 
breaks within cells in the nasal mucosa. These data need 
to be confirmed by clinical trials involving treatment with 
different ICs over longer periods.
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